



November 10, 2022

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

Notice Concerning Conclusion of Joint Research and Development Agreement with BioSafety Research Center Inc.

AnGes, Inc. announces that on November 10, 2022, it entered into a joint research and development agreement with BioSafety Research Center Inc. (President: Kenji Fukunaga; Head Office: Iwata City, Shizuoka Prefecture; hereinafter referred to as "BSRC") on transgenic zebrafish* (hereinafter referred to as "TGZF") models for drug screening purposes, as described below.

Although this matter is not subject to timely disclosure as stipulated by the Tokyo Stock Exchange, we are voluntarily disclosing this information because we believe it is useful information.

1. Reasons for Joint Research and Development

In this joint research and development project, AnGes will cooperate with BSRC in the development of the TGZF model by providing advice on the evaluation of the response and validation of the usefulness of the TGZF model in which our development product is administered, and in establishing the TGZF model and evaluation method..

AnGes will be involved in the development process of the TGZF model and will incorporate the acquired data into the research and development of the developed product..

BSRC is developing technologies and creating animal models for the purpose of establishing a drug discovery support service system using TGZF, and plans to widely deploy drug discovery screening services using said TGZF models after the completion of said TGZF models, aiming to further enhance the corporate value of both companies together with the improvement of AnGes' drug development technologies.

2. Details of Joint Research and Development

AnGes will provide NF- κ B decoy oligo DNA and other inflammation-related agents under development to validate the usefulness of the TGZF model.

BSRC will create a TGZF model that can confirm GFP expression by inflammatory stimuli and response to drugs, and will administer drugs developed by the Company in order to commercialize the TGZF model.

3. Outline of joint research partners

Name : BioSafety Research Center Inc.

Location : 582-2 Shio-shinden, Iwata City, Shizuoka Prefecture

(Note) This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.



Representative : Kenji Fukunaga, President and Representative Director

Business Description : Contract research and testing on the safety of chemical substances, mainly pharmaceuticals and agrochemicals

Commissioned production of genetically engineered mice, sales of model mice, and contracted non-clinical studies using the produced model mice.

Capital : 100 million yen.

BSRC plays a central role in the drug discovery support business by providing data on safety testing of chemicals such as pharmaceuticals, foods, food additives, pesticides, feed additives, and general industrial chemicals based on high science and reliability at well-established GLP (Good Laboratory Practice) and AAALAC (International Association for the Evaluation and Certification of Laboratory Animal Care) certified facilities, backed by the track record and trust accumulated over the 40 years since its establishment. BSRC is one of the few companies in Japan with facilities and researchers capable of conducting the eco-toxicity studies required for registration applications for pesticides using aquatic animals, and has a strong track record in contract research.

4. Future outlook

The impact of this joint research and development on the consolidated financial results for the fiscal year ending December 31, 2022 will be minimal. We will promptly announce any matters that should be disclosed in the future.

*Zebrafish

Zebrafish are in increasing demand due to their characteristics, such as approximately 80% disease genome similarity to humans, high extrapolation to humans, and ease of screening.